Research analysts at Wedbush began coverage on shares of Crescent Biopharma (NASDAQ:CBIO - Get Free Report) in a report released on Monday, MarketBeat.com reports. The firm set an "outperform" rating and a $27.00 price target on the biopharmaceutical company's stock. Wedbush's price target would indicate a potential upside of 108.98% from the company's previous close. Wedbush also issued estimates for Crescent Biopharma's Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.30) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($2.96) EPS, FY2027 earnings at ($6.38) EPS, FY2028 earnings at ($4.54) EPS and FY2029 earnings at ($4.48) EPS.
CBIO has been the topic of a number of other research reports. Stifel Nicolaus assumed coverage on Crescent Biopharma in a research note on Wednesday, June 25th. They set a "buy" rating and a $28.00 price objective on the stock. TD Cowen upgraded shares of Crescent Biopharma to a "strong-buy" rating in a research report on Friday, June 20th. Lifesci Capital upgraded Crescent Biopharma to a "strong-buy" rating and set a $22.00 price objective on the stock in a report on Wednesday, June 18th. Finally, Wall Street Zen raised shares of Crescent Biopharma to a "sell" rating in a research note on Saturday, July 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Crescent Biopharma has a consensus rating of "Buy" and a consensus price target of $25.67.
Read Our Latest Stock Analysis on CBIO
Crescent Biopharma Stock Performance
NASDAQ CBIO traded down $0.22 during mid-day trading on Monday, hitting $12.92. The stock had a trading volume of 69,696 shares, compared to its average volume of 33,344. The company has a market cap of $252.59 million, a P/E ratio of -0.28 and a beta of 1.52. Crescent Biopharma has a twelve month low of $11.06 and a twelve month high of $63.00.
About Crescent Biopharma
(
Get Free Report)
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Read More
Before you consider Crescent Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.
While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
